Decode Duchenne provides diagnostic testing for Duchenne and Becker muscular dystrophy. Decode Duchenne is a Collaborative partnership between Parent Project Muscular Dystrophy (PPMD), Sarepta Therapeutics and other industry partners, and Revvity Omics.
Since 2013, PPMD has been proud to offer free genetic testing, counseling support, and education through Decode Duchenne. Decode Duchenne offers free genetic testing to people in the Becker and Duchenne muscular dystrophy community who otherwise would be unable to access genetic testing. For asymptomatic carrier testing, please visit PPMD’s website and submit an application.
You can also access free genetic counseling support for Duchenne and Becker muscular dystrophy at PPMD at 888-520-8675 (option 1) or emailing [email protected].
For Health Care Professionals already familiar with Duchenne and Becker muscular dystrophy, feel free to use the links below to order a kit or submit a sample.
Identifying the underlying cause of your patient’s chronic anemia can make a big difference to your patient’s life. That’s why Agios Pharmaceuticals has partnered with Revvity Omics to offer Anemia ID: a free genetic testing program. Anemia ID provides a next-generation sequencing (NGS) panel for a wide range of rare hereditary anemias.
In collaboration with Revvity Omics (formerly PerkinElmer Genomics), Sanofi Canada has launched the Roadmap2Rare Diagnostic Program, a sponsored testing program that covers enzymatic activity, biomarker, and genetic testing for several rare lysosomal storage diseases. The program also provides access to multi-gene panels that include common differential diagnoses for Pompe and Fabry disease. Metabolic genotyping for Gaucher disease type 1 (when applicable to certain treatment considerations) is available separately in collaboration with ARCHIMEDlife.
Launched by Sanofi Genzyme with PerkinElmer Genomics (now Revvity Omics), The Lantern Project provides no-cost testing for patients whom physicians suspect may be suffering from Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis type I (MPS I), or acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B. Additionally, there is the option of an enzyme panel for seven mucopolysaccharidoses and a 105 gene panel for limb-girdle muscular dystrophies (LGMD) and other myopathies.